医药行业观点更新&来凯医药深度汇报 20250709 莱凯医药 L1A102 在激活素受体通路上选择性更强，安全性更优，可皮 下给药。一期临床数据显示安全性良好，多剂量递增研究正在进行中， 预计 2023 年三季度读出数据（注：原文时间，需更新）。 AKT 抑制剂是癌症治疗的重要手段，AZ 公司的 Kapi 已获 FDA 批准上 市，2024 年销售额达 4.3 亿美元。莱凯医药的 AKT 抑制剂正进行乳腺 癌三期临床，计划明年上半年申报上市，早期数据显示 PFS 与 AZ 数据 相当。 创新药泡沫化问题以及中国与美国 FDA 之间的差距如何影响未来发展？ 创新药目前尚未达到真正泡沫化阶段，与几年前中国疫苗产业相比仍有较大差 距。此外，中国临床及研发效益不断提升，但与美国 FDA 之间仍未完全接轨， 这意味着中国创新药改革仍有空间和余地。临床前研发效率提升空间依然存在， 美国市场对中国产品认可度和开放程度也支撑了创新药发展的底层逻辑。因此， 布局创新药仍是值得关注的方向。 摘要 创新药市场情绪回暖，下半年 BD 事件或将增多，与 2018 年医药行业 景气度回升相似，中国创新药和药政改革成果逐步显现，但尚未达 ...

Core Insights - Hepsor Phoenix 4 OÜ has signed a construction contract for the M12 development project in Tallinn, valued at 7.0 million euros, with completion expected in the second half of 2026 [1][3] - The M12 project will feature two apartment buildings with a total of 49 apartments and a saleable area of 3,090 m² [1] - The development emphasizes energy efficiency and sustainability, incorporating smart home systems, electric vehicle charging, solar panels, and storage for bicycles and strollers [2] Company Developments - The M12 project is the fourth collaboration between Hepsor and the Tolaram Group in the Manufaktuuri quarter, following the completion of 421 homes in previous projects, with 96% sold [4] - Construction for the first phase of the Manufaktuuri Factory project, which will add 152 new homes, is planned to start in the third quarter of 2025 [4] - Hepsor AS has developed 2,076 homes and nearly 36,300 m² of commercial space over 14 years, and is recognized for implementing innovative engineering solutions for energy efficiency [4]

2025年7月8日 ， 瑞士医疗科技公司 Aktiia 宣布，其 G0无袖带血压监测系统 获得美国食品药品监督管理局（FDA）510(k)批准。 这是全球首款被批准可作为非处方 （OTC）产品上市的无袖带血压监测可穿戴设备，标志着血压管理从传统袖带向无创、连续、可穿戴技术的转折点。 G0系统计划于 2026年 在美国上市，初期将通过零售药店、电商和医疗渠道销售，预计售价在300美元左右。此前，该系统已 获得CE认证，并 在欧洲多个国家以 Hilo品牌销售。 # 无袖带血压监 测的 核心突破 Aktiia G0系统（美国市场称为Hilo Band），核心技术基于 光体积描记法（PPG） ，通过佩戴在手腕上的光学传感器，捕捉血管随心跳产生的微小体积变化，结合自 研的 CALFREE算法 ，实时估算收缩压（SBP）与舒张压（DBP）。 传统的血压监测依赖充气袖带，虽然精准，但存在几个痛点：测量过程需要主动操作，患者往往难以坚持；袖带反复充气造成不适，特别是夜间监测干扰睡眠；测 量频率低，可能漏掉血压波动。 G0系统针对这些问题，做出了以下技术突破： 虽然精度略低于传统袖带设备，但在连续性和用户体验方面，G0系统实现 ...

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, has been named the top Leader in the Everest Group Analytics and Artificial Intelligence (AI) Services Specialists PEAK Matrix® Assessment 2025, for the second consecutive year. The Everest Group report examined 32 leading providers who derive more than 50% of their revenue from analytics and AI services on their ability to meet enterprise needs and deliver scalable, secure and high-impact AI and data solutions. EX ...

Daktronics (DAKT) Q4 2025 Earnings Call June 25, 2025 11:00 AM ET Company Participants Carla Gatzke - VP - Human Resources & Corporate SecretaryAndrew Siegel - ChairmanBrad Wiemann - EVP, Interim President & CEOHoward Atkins - Acting CFO, Treasurer & Chief Transformation Officer Conference Call Participants Aaron Spychalla - Senior Research AnalystAnja Soderstrom - Senior Equity Research AnalystMac Furst - Research Analyst Operator Good day, and thank you for standing by. Welcome to the Daktronics Fourth Qu ...

Financial Data and Key Metrics Changes - The company reported a strong finish to a transformational year, with a 29% increase in backlog from Q3 and a 17% year-over-year increase [15][39] - Adjusted operating income for 2025 was $50 million, down from a record $87 million in 2024, with an adjusted operating income margin of 6.6% compared to 10.6% in 2024 [36][39] - Operating cash flow more than doubled year-over-year, with a 54.5% growth for the year, totaling $97.7 million [32][41] Business Line Data and Key Metrics Changes - In the Live Events segment, orders decreased 12% year-over-year, but the company expects continued growth due to new projects and repeat customers [20][18] - The Commercial business saw a 31% increase in orders for the year and a 44% increase in Q4 compared to the previous year, driven by strong demand in out-of-home advertising [21][22] - Transportation orders decreased 10% year-over-year but increased 14% from Q4, supported by notable wins in intelligent transportation systems [23][24] Market Data and Key Metrics Changes - International orders grew 32% year-over-year and more than doubled from Q4 of the previous year, with significant contributions from advertising orders in various countries [25][26] - The High School Park and Recreation business experienced record orders, growing 19% for the year and 33% for Q4, driven by strong adoption of video solutions [27][28] Company Strategy and Development Direction - The company is focused on achieving higher operating margins of 10% to 12% and a return on invested capital (ROIC) target of 17% to 20% by fiscal year 2028 [47] - The transformation plan includes value-based pricing, revenue mix diversification, and new product introductions to drive growth [48] - The company is committed to maintaining a strong balance sheet and investing in high-growth, high-margin business products [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue growth in FY 2026, supported by a strong backlog and order flow [55][39] - The company is adapting to the tariff environment and remains flexible in its pricing and supply chain strategies [49][50] - Management emphasized the importance of executing the transformation plan and achieving long-term financial objectives [51][52] Other Important Information - The company incurred $16.5 million in non-recurring expenses related to transformation initiatives, with $7.5 million in Q4 [34][35] - A new $10 million share repurchase program was approved by the board, following a previous program [76] Q&A Session Summary Question: Revenue growth outlook for FY 2026 - Management indicated that all markets are expected to show growth, aligning with the 7% to 10% compound annual growth rate target through FY 2028 [55][56] Question: Margin outlook and tariff impacts - Management discussed implementing value-based pricing and driving operational efficiencies to improve margins, despite tariff uncertainties [57][58] Question: Update on commercial segment and AV network expansion - Management highlighted optimism in the commercial business, particularly in out-of-home advertising, and plans to aggressively grow the AV integrator space [60][61] Question: Working capital and capital allocation - Management stated that the primary use of capital will be for growth initiatives, product development, and digital transformation, with share repurchase also being considered [64][66] Question: Strength of international orders and future expectations - Management noted significant growth in international orders and a strong pipeline, which is expected to contribute to revenue growth in FY 2026 [72][73] Question: Future consulting fees related to transformation initiatives - Management confirmed that no additional consulting fees are expected for the completed transformation initiatives, but some new initiatives may arise [74][75]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][4] - The company has developed its first novel payload, PH1, which is a spliceosome inhibitor designed to disrupt RNA splicing within cells, differentiating it from current ADC payloads [4] Recent Developments - Akari Therapeutics recently participated in a Virtual Investor segment where CEO Abizer Gaslightwala discussed the issuance of India Patent No. 562,919 for "Thailanstatin Analogs," which covers claims for its PH1 payload and ADC technology [3] - The PH1 payload has shown significant activity in preclinical studies, inducing cancer cell death and activating immune cells, leading to robust and durable activity [4] Product Pipeline - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors [4] - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has potential synergistic effects with checkpoint inhibitors [4]

来凯医药 20250616 来凯医药将在本月 20 号召开的美国 ADA 大会上展示两份重要内容。首先是 L102 针对肥胖症的临床一期 SAD 详细数据报告。其次是 L1,102,103 和 123 的临床前动物实验探索，特别是 AKT1 和 AKT2 两个不同靶点作用机制的数据 验证。这些数据将首次发表，展示来凯医药在信号通道上的全球领先探索。 来凯医药在减肥药市场上的研发策略是什么？ 来凯医药在减肥药市场上致力于开发高质量的减脂不减肌方案。公司依托创业 团队 30 多年的深耕，目前全球唯一一家对 ICAR-2 信号传导路径中的 a 和 b 两 个受体进行单独靶点抑制，拥有 ICAR-TWO-A、ICAR-TWO-B 以及 ICAR- TWO-AB 三款抗体，实现全方位布局。在此次 ADA 大会上，公司将汇报去年 AKT 抑制剂 L1,002 是全球第二款、国内首款，正进行新药申请，临床 数据与阿斯利康 Capivasertib 类似，但安全性更佳，预计国内 HER2 阳性乳腺癌适应症销售峰值可达十几至二十亿人民币。 礼来收购 Gubra 表明其重视增肌方向，并积极布局该领域。礼来将在 6 月 23 日公 ...

Group 1 - The company, formerly known as Unifiedpost Group SA, will change its ticker symbol on Euronext Brussels from "UPG" to "BANQ" effective 19 June 2025 [1][2] - The rebranding to Banqup Group SA was approved at the Extraordinary General Meeting on 20 May 2025, aligning the ticker symbol with the company's Banqup platform [2] - The company focuses on core digital services, positioning itself as a pure-play SaaS provider, with a commitment to growth in e-invoicing and payment solutions [2][3] Group 2 - Banqup Group delivers integrated cloud-based SaaS solutions that streamline business transactions, including e-invoicing, e-payments, and tax reporting [3] - The Banqup solution unifies various business processes into one secure platform, simplifying operations for users [3] - The eFaktura World solution is designed for governments to implement e-invoicing and streamline tax reporting flows for both B2G and B2B [3]

Core Viewpoint - The investment association Maj Invest has updated the prospectuses for several departments due to an addition to the investor target group for the respective w-share classes [1]. Group 1: Updated Prospectuses - The updated prospectuses pertain to the following departments: Danske Aktier KL, Emerging Markets Value KL, Globale Aktier non fossil KL, Grønne Obligationer KL, Net Zero 2050 KL, Planet & People KL, Value Aktier Akkumulerende KL, Value Aktier KL, and Vækstaktier KL [4][5]. Group 2: Contact Information - For any inquiries, Lise Bøgelund Jensen, the director of the association's investment management company, can be contacted at phone number 33 28 28 28 [2].